We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

The HPV vaccine, called Gardasil-9 — which has no live virus and is completely non-infectious — protects against the six types of HPV most likely to cause cancer, Eckert says. (These are strains 6, 11 ...

A class action lawsuit is brewing against Merck & Co. over claims of securities fraud, and investors aren’t exactly raising a ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous ...